ENTO
GridAI Technologies Corp.2.9900
+0.1500+5.28%
Nov 28, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
10.05MP/E (TTM)
-Basic EPS (TTM)
-11.66Dividend Yield
0%Recent Filings
8-K
Unwinds ImmunoX acquisition
GridAI Technologies completed the rescission of its ImmunogenX acquisition on December 31, 2025, transferring all Immuno LLC membership interests back to former shareholders. This unwinds the March 2024 merger, slashing total assets from $135M to $52M pro forma as of September 30, 2025, by removing $83M in held-for-sale assets and related liabilities. Continuing operations now stand alone. Pro forma loss per share improves to $(1.77) from $(2.28).
8-K
Sawyer named permanent CEO
GridAI Technologies promoted Jason D. Sawyer from interim to permanent CEO via an amended consulting agreement with Access Alternative Group, effective December 19, 2025, for a two-year term. Compensation includes $25,000 monthly base (retroactive to October 1), $20,000 quarterly Nasdaq compliance fees, 1M RSUs vesting quarterly in 2026, and $150,000 plus 400,000 shares upon Grid AI acquisition approval. Sawyer leads operations remotely. Termination risks severance without cause.
8-K
Name change, director exits
GridAI Technologies (formerly Entero Therapeutics) changed its name and Nasdaq ticker to GRDX, effective December 1, 2025, aligning with its recent GRID AI acquisition. Directors Eric Corbett and Richard Paolone resigned November 28 amid Corbett's concerns over financial disclosures, AI due diligence, and governance. Company paid Paolone $500,000 plus $50,000 legal fees via separation agreement. Board committees restructured.
10-Q
Q3 FY2025 results
Entero Therapeutics narrowed its Q3 operating loss to $0.9M from $1.9M y/y, while YTD loss from continuing ops eased to $2.6M from $3.8M y/y as R&D plunged 97% to $7K and G&A fell 45% to $0.9M. Cash climbed to $2.5M on $3.0M equity raises and a $0.7M revolver draw (18% rate, $1.3M available), yet burn persists at $1.7M YTD from ops. Closed Grid AI acquisition Sep 30 for $2.1M common stock/ $25.0M Series H preferred (convertible to 38.8M shares post-approval), booking $25.8M goodwill and $21.8M intangibles (10-year lives). IMGX assets ($83.2M)/liabilities ($23.7M) held for sale. Nasdaq eyes delisting post-change of control.
8-K
GridAI waives director rights
Entero Therapeutics stockholders of GridAI waived their right to appoint two directors to the company's board on October 17, 2025, as per the September 30 Share Exchange Agreement. This holds until Entero shareholders approve the appointments at a duly called meeting. Waiver delays board changes amid merger process.
ABEO
Abeona Therapeutics Inc.
5.00-0.08
ATOS
Atossa Therapeutics, Inc.
0.72+0.01
CYTOF
Altamira Therapeutics Ltd.
0.07+0.00
ENTA
Enanta Pharmaceuticals, Inc.
14.85-0.02
ENTX
Entera Bio Ltd.
2.09+0.01
EXOZ
eXoZymes Inc.
12.52-1.78
GLTO
Galecto, Inc.
30.00-1.60
SLNO
Soleno Therapeutics, Inc.
49.50-0.45
TRDA
Entrada Therapeutics, Inc.
11.37+0.34
ZNTL
Zentalis Pharmaceuticals, Inc.
1.38-0.02